TPST-1120

DRUG3 trials

Sponsors

F. Hoffmann-La Roche AG, Hoffmann-La Roche, Tempest Therapeutics

Conditions

Advanced Liver CancersAdvanced liver cancersHepatocellular Carcinoma (HCC)

Phase 1

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

RecruitingNCT04524871

Hoffmann-La RocheAdvanced Liver Cancers

Start: 2020-11-01End: 2027-12-31Target: 518Updated: 2026-03-27

A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH ADVANCED LIVER CANCERS (MORPHEUS LIVER)

Not yet recruitingCTIS2023-506611-17-00

F. Hoffmann-La Roche AGAdvanced liver cancers

Target: 29Updated: 2025-12-04

Phase 3

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Not yet recruitingNCT06680258

Tempest TherapeuticsHepatocellular Carcinoma (HCC)

Start: 2025-12-31End: 2030-07-31Target: 740Updated: 2025-09-03

Related Papers

PROSPERO: A phase 3 randomized, placebo (Pbo)-controlled study of amezalpat (TPST-1120), a peroxisome proliferator-activated receptor a (PPARα) inhibitor, in combination with atezolizumab + bevacizumab (AB) for patients (pts) with unresectable or metastatic hepatocellular carcinoma (mHCC) not previously treated with systemic therapy.

Journal of Clinical Oncology2025-05-28

Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.

2025-01-2141 citations

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Cancer Research Communications2024-03-2914 citations

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events

Journal for ImmunoTherapy of Cancer2023-06-0183 citations

Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).

Journal of Clinical Oncology2023-06-0149 citations